Does the media refer more to NVAX or VNDA?

In the previous week, Novavax had 5 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Novavax's score of -0.01 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNKD or VNDA?

In the previous week, MannKind had 10 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 13 mentions for MannKind and 3 mentions for Vanda Pharmaceuticals. MannKind's average media sentiment score of 0.93 beat Vanda Pharmaceuticals' score of 0.53 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LXRX or VNDA?

In the previous week, Lexicon Pharmaceuticals had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 6 mentions for Lexicon Pharmaceuticals and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Lexicon Pharmaceuticals' score of 0.51 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or GERN?

In the previous week, Geron had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Geron and 3 mentions for Vanda Pharmaceuticals. Geron's average media sentiment score of 1.15 beat Vanda Pharmaceuticals' score of 0.53 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or OPK?

In the previous week, OPKO Health had 24 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 27 mentions for OPKO Health and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat OPKO Health's score of 0.35 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 4 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Vanda Pharmaceuticals (VNDA) Competitors

$5.10 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.36 +0.26 (+5.18%)

As of 07/31/2026 07:43 PM Eastern

Compare

VNDA vs. NVAX, MNKD, LXRX, GERN, and OPK

Should you buy Vanda Pharmaceuticals stock or one of its competitors? MarketBeat compares Vanda Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vanda Pharmaceuticals include Novavax (NVAX), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), Geron (GERN), and OPKO Health (OPK).

How does Vanda Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Novavax has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Novavax had 5 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Novavax's score of -0.01 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a net margin of -14.73% compared to Vanda Pharmaceuticals' net margin of -109.99%. Novavax's return on equity of -14.82% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Novavax has higher revenue and earnings than Vanda Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.07	$440.30M	-$0.58	N/A
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.05	N/A

Novavax presently has a consensus price target of $13.00, suggesting a potential upside of 77.60%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 180.39%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Novavax beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

MannKind has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

MannKind has higher revenue and earnings than Vanda Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.05	N/A

MannKind currently has a consensus target price of $9.34, suggesting a potential upside of 138.97%. Vanda Pharmaceuticals has a consensus target price of $14.30, suggesting a potential upside of 180.39%. Given Vanda Pharmaceuticals' higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, MannKind had 10 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 13 mentions for MannKind and 3 mentions for Vanda Pharmaceuticals. MannKind's average media sentiment score of 0.93 beat Vanda Pharmaceuticals' score of 0.53 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a net margin of -6.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. MannKind's return on equity of -11.21% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

49.6% of MannKind shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MannKind beats Vanda Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Lexicon Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, suggesting a potential upside of 96.97%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 180.39%. Given Vanda Pharmaceuticals' higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Lexicon Pharmaceuticals had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 6 mentions for Lexicon Pharmaceuticals and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Lexicon Pharmaceuticals' score of 0.51 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Vanda Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.60	-$50.34M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.05	N/A

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Vanda Pharmaceuticals' net margin of -109.99%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Summary

Lexicon Pharmaceuticals beats Vanda Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Geron?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vanda Pharmaceuticals currently has a consensus price target of $14.30, suggesting a potential upside of 180.39%. Geron has a consensus price target of $4.00, suggesting a potential upside of 210.08%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Geron had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Geron and 3 mentions for Vanda Pharmaceuticals. Geron's average media sentiment score of 1.15 beat Vanda Pharmaceuticals' score of 0.53 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has lower revenue, but higher earnings than Vanda Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.05	N/A
Geron	$183.88M	4.50	-$83.50M	-$0.11	N/A

Geron has a net margin of -35.48% compared to Vanda Pharmaceuticals' net margin of -109.99%. Geron's return on equity of -23.31% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Geron	-35.48%	-23.31%	-10.08%

Summary

Geron beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to OPKO Health?

Vanda Pharmaceuticals (NASDAQ:VNDA) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 44.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vanda Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.05	N/A
OPKO Health	$606.90M	1.62	-$225.68M	-$0.09	N/A

Vanda Pharmaceuticals presently has a consensus price target of $14.30, suggesting a potential upside of 180.39%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 17.42%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, OPKO Health had 24 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 27 mentions for OPKO Health and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat OPKO Health's score of 0.35 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	4 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

OPKO Health has a net margin of -12.40% compared to Vanda Pharmaceuticals' net margin of -109.99%. OPKO Health's return on equity of -5.88% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
OPKO Health	-12.40%	-5.88%	-3.83%

Summary

OPKO Health beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$306.66M	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-1.26	799.05	282.30	24.66
Price / Sales	1.42	752.17	561.34	76.65
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	0.92	10.36	10.98	6.07
Net Income	-$220.47M	$2.82B	$3.49B	$347.99M
7 Day Performance	-2.30%	-0.10%	-0.60%	-0.44%
1 Month Performance	-17.87%	-3.96%	-5.20%	-4.81%
1 Year Performance	21.72%	156.17%	62.01%	18.61%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.7576 of 5 stars	$5.10 flat	$14.30 +180.4%	+21.7%	$306.66M	$216.10M	N/A	290	Upcoming Earnings
NVAX Novavax	2.0075 of 5 stars	$7.49 +0.4%	$13.00 +73.6%	+11.6%	$1.23B	$1.12B	N/A	1,990	Upcoming Earnings Analyst Downgrade
MNKD MannKind	3.1738 of 5 stars	$3.95 -4.4%	$8.97 +127.1%	+4.3%	$1.22B	$348.97M	N/A	400	Upcoming Earnings
LXRX Lexicon Pharmaceuticals	1.7996 of 5 stars	$2.23 -2.6%	$4.55 +104.0%	+115.9%	$990.57M	$49.80M	N/A	140	Positive News Upcoming Earnings
GERN Geron	2.5583 of 5 stars	$1.48 +4.2%	$4.00 +170.3%	+10.3%	$949.45M	$183.88M	N/A	70	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. NVAX, MNKD, LXRX, GERN, and OPK

How does Vanda Pharmaceuticals compare to Novavax?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. NVAX, MNKD, LXRX, GERN, and OPK

How does Vanda Pharmaceuticals compare to Novavax?

Which has more risk & volatility, NVAX or VNDA?

Do insiders & institutionals hold more shares of NVAX or VNDA?

Does the media refer more to NVAX or VNDA?

Is NVAX or VNDA more profitable?

Which has preferable earnings and valuation, NVAX or VNDA?

Do analysts rate NVAX or VNDA?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Which has more risk & volatility, MNKD or VNDA?

Which has preferable valuation & earnings, MNKD or VNDA?

Do analysts prefer MNKD or VNDA?

Does the media refer more to MNKD or VNDA?

Is MNKD or VNDA more profitable?

Do institutionals and insiders hold more shares of MNKD or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Which has more volatility and risk, LXRX or VNDA?

Do analysts rate LXRX or VNDA?

Does the media favor LXRX or VNDA?

Which has preferable earnings & valuation, LXRX or VNDA?

Do institutionals & insiders hold more shares of LXRX or VNDA?

Is LXRX or VNDA more profitable?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Which has more risk and volatility, VNDA or GERN?

Do insiders and institutionals hold more shares of VNDA or GERN?

Do analysts recommend VNDA or GERN?

Does the media prefer VNDA or GERN?

Which has preferable valuation and earnings, VNDA or GERN?

Is VNDA or GERN more profitable?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Which has more risk and volatility, VNDA or OPK?

Do institutionals and insiders hold more shares of VNDA or OPK?

Which has better valuation and earnings, VNDA or OPK?

Do analysts prefer VNDA or OPK?

Does the media prefer VNDA or OPK?

Is VNDA or OPK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools